Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2024 Filed Sep 13, 2024 23:07 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 25,000 | $57.92 | $1,448,000.00 |
DisclosureSEC source: 0001127602-24-023946 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:20 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,641 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023815 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,127 Underlying: Common Stock · 3,641 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:20 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 1,682 | $81.44 | $136,982.08 |
DisclosureSEC source: 0001127602-24-023815 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,919 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:20 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 3,641 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023815 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:23 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023817 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,945 Underlying: Common Stock · 3,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:23 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 1,734 | $81.44 | $141,216.96 |
DisclosureSEC source: 0001127602-24-023817 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,484 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:23 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 3,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023817 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:30 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023819 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,272 Underlying: Common Stock · 10,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:30 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 4,749 | $81.44 | $386,758.56 |
DisclosureSEC source: 0001127602-24-023819 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,995 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:30 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 10,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023819 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:33 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,821 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023821 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,573 Underlying: Common Stock · 3,821 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:33 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 1,766 | $81.44 | $143,823.04 |
DisclosureSEC source: 0001127602-24-023821 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,435 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:33 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 3,821 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023821 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:38 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionRestricted Stock Unit · Derivative | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023823 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,183 Underlying: Common Stock · 901 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:38 UTC |
Patterson SandraSVP, Controllership
|
Tax withholdingCommon Stock | 292 | $81.44 | $23,780.48 |
DisclosureSEC source: 0001127602-24-023823 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,585 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:38 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionCommon Stock | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023823 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:41 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionRestricted Stock Unit · Derivative | 639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023825 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,547 Underlying: Common Stock · 639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:41 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Tax withholdingCommon Stock | 307 | $81.44 | $25,002.08 |
DisclosureSEC source: 0001127602-24-023825 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,707 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:41 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionCommon Stock | 639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023825 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 19:23 UTC |
Mercier JohannaChief Commercial Officer
|
SaleCommon Stock | 9,513 | $78.03 | $742,299.39 |
DisclosureSEC source: 0001127602-24-023128 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,466 F1 · kind: The sale transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on April 30, 2024. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 18:23 UTC |
Mercier JohannaChief Commercial Officer
|
SaleCommon Stock | 5,490 | $73.98 | $406,150.20 |
DisclosureSEC source: 0001127602-24-022176 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,979 F1 · kind: The sale transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on April 30, 2024. Read SEC document |
| August 10, 2024 Filed Aug 12, 2024 20:22 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,678 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-022009 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,084 Underlying: Common Stock · 3,678 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2024 Filed Aug 12, 2024 20:22 UTC |
Patterson SandraSVP, Controllership
|
Tax withholdingCommon Stock | 980 | $73.66 | $72,186.80 |
DisclosureSEC source: 0001127602-24-022009 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,976 Read SEC document |
| August 10, 2024 Filed Aug 12, 2024 20:22 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionCommon Stock | 3,678 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-022009 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,230 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · derivative · entry 5 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,186 Underlying: Common Stock · 8,230 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of the grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of the grant until fully vested. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionRestricted Stock Unit · Derivative | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · derivative · entry 4 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,416 Underlying: Common Stock · 514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionCommon Stock | 8,230 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · nonDerivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionCommon Stock | 514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:28 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Tax withholdingCommon Stock | 2,917 | $76.51 | $223,179.67 |
DisclosureSEC source: 0001127602-24-021048 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,631 Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 00:06 UTC |
Parsey MerdadChief Medical Officer
|
SaleCommon Stock | 2,000 | $68.63 | $137,260.00 |
DisclosureSEC source: 0001127602-24-019650 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,380 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:12 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionRestricted Stock Unit · Derivative | 638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018411 · form4.xml · derivative · entry 3 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,930 Underlying: Common Stock · 638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:12 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Tax withholdingCommon Stock | 204 | $65.25 | $13,311.00 |
DisclosureSEC source: 0001127602-24-018411 · form4.xml · nonDerivative · entry 2 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,548 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:12 UTC |
Telman Deborah HEVP, Corporate Affairs & GC
|
Exercise / conversionCommon Stock | 638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018411 · form4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:15 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018413 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,394 Underlying: Common Stock · 3,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:15 UTC |
Parsey MerdadChief Medical Officer
|
Tax withholdingCommon Stock | 1,744 | $65.25 | $113,796.00 |
DisclosureSEC source: 0001127602-24-018413 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,380 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:15 UTC |
Parsey MerdadChief Medical Officer
|
Exercise / conversionCommon Stock | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018413 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:18 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018415 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,697 Underlying: Common Stock · 3,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:18 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 1,714 | $65.25 | $111,838.50 |
DisclosureSEC source: 0001127602-24-018415 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,469 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:18 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 3,751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018415 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:20 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018417 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,567 Underlying: Common Stock · 10,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:20 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 4,693 | $65.25 | $306,218.25 |
DisclosureSEC source: 0001127602-24-018417 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,449 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:20 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 10,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018417 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:23 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionRestricted Stock Unit · Derivative | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018419 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,762 Underlying: Common Stock · 901 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:23 UTC |
Patterson SandraSVP, Controllership
|
Tax withholdingCommon Stock | 255 | $65.25 | $16,638.75 |
DisclosureSEC source: 0001127602-24-018419 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,278 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:23 UTC |
Patterson SandraSVP, Controllership
|
Exercise / conversionCommon Stock | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018419 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:25 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018421 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,768 Underlying: Common Stock · 3,639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:25 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 1,662 | $65.25 | $108,445.50 |
DisclosureSEC source: 0001127602-24-018421 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,960 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:25 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 3,639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018421 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 08, 2024 Filed May 9, 2024 19:38 UTC |
Kramer Kelly A.Director
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 12,648 | $0.00 Strike: $64.92 | $0.00 |
DisclosureSEC source: 0001127602-24-014764 · form4.xml · derivative · entry 2 Kramer Kelly A. · CIK 0001629885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,648 Underlying: Common Stock · 12,648 shares Expires 2034-05-08 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024. Read SEC document |
| May 08, 2024 Filed May 9, 2024 19:38 UTC |
Kramer Kelly A.Director
|
GrantRestricted Stock Unit · Derivative | 2,310 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-014764 · form4.xml · derivative · entry 1 Kramer Kelly A. · CIK 0001629885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,594 Underlying: Common Stock · 2,310 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024. F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.